DESTINY-Breast03 Phase 3 Study Results
Baseline Patient and Disease Characteristics
DS-6000a Dose Escalation
OVC
(N=20)
Age, median (range), years
65.5 (51-78)
RCC
(N=9)
60.0 (41-72)
Total
(N=30)a
64.5 (41-78)
Sex, n (%)
Female
20 (100)
4 (44.4)
25 (83.3)
Male
0
5 (55.6)
5 (16.7)
Baseline ECOG PS, n (%)
0
10 (50)
6 (66.7)
16 (53.3)
1
10 (50)
3 (33.3)
14 (46.7)
Tumor type, n (%)
Renal cell carcinoma
Clear cell RCC
Non-clear cell RCC
Serous ovarian cancer
Platinum-resistant disease
-
8 (88.9)
1 (11.1)
8 (26.7)
1 (3.3)
20 (100)
20 (66.7)
17 (85)
17 (56.7)
No. of prior systemic regimens
Median (range)
4.0 (1-12)
Baseline CDH6 expression H score, range
0-250
2.0 (1-6)
17-218
3.0 (1-12)
0-250b
Data cutoff: February 25, 2022.
CDH6, cadherin 6; ECOG PS, Eastern Cooperative Oncology Group performance status; OVC, ovarian cancer; RCC, renal cell carcinoma.
a One missing primary diagnosis of OVC.
b Membrane CDH6 expression of 23 evaluable archival tissues.
ASCO 2022 #3002 Oral
Daiichi-Sankyo
100View entire presentation